Orexo Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Orexo de 71.8% y 11.3% respectivamente, mientras que el BPA crecerá en un 71.8% al año.

Información clave

71.8%

Tasa de crecimiento de los beneficios

71.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	73.2%
Tasa de crecimiento de los ingresos	11.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	25 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 20

Recent updates

Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 05

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Aug 02

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 20

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Sep 09

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

May 26

Is Orexo (STO:ORX) Using Too Much Debt?

Apr 16

Previsiones de crecimiento de beneficios e ingresos

OM:ORX - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	686	-20	58	63	1
12/31/2025	583	-79	-4	N/A	1
12/31/2024	584	-120	-37	-32	1
9/30/2024	596	-105	-46	-41	N/A
6/30/2024	615	-97	-61	-50	N/A
3/31/2024	619	-73	-72	-52	N/A
12/31/2023	639	-128	-114	-95	N/A
9/30/2023	629	-201	-172	-141	N/A
6/30/2023	634	-195	-205	-180	N/A
3/31/2023	624	-218	-176	-157	N/A
12/31/2022	624	-178	-180	-157	N/A
9/30/2022	612	-152	-203	-188	N/A
6/30/2022	597	-177	-241	-207	N/A
3/31/2022	592	-216	-285	-243	N/A
12/31/2021	565	-223	-282	-229	N/A
9/30/2021	580	-207	-239	-160	N/A
6/30/2021	585	-240	-201	-93	N/A
3/31/2021	621	-198	-281	-79	N/A
12/31/2020	664	-84	-173	17	N/A
9/30/2020	743	4	-94	84	N/A
6/30/2020	824	201	89	231	N/A
3/31/2020	846	288	248	284	N/A
12/31/2019	845	219	255	287	N/A
9/30/2019	834	232	286	302	N/A
6/30/2019	819	182	192	194	N/A
3/31/2019	818	178	183	187	N/A
12/31/2018	783	138	238	242	N/A
9/30/2018	747	113	144	147	N/A
6/30/2018	697	79	N/A	215	N/A
3/31/2018	656	32	N/A	225	N/A
12/31/2017	644	23	N/A	147	N/A
9/30/2017	637	19	N/A	241	N/A
6/30/2017	653	27	N/A	191	N/A
3/31/2017	682	29	N/A	151	N/A
12/31/2016	706	29	N/A	156	N/A
9/30/2016	752	-57	N/A	84	N/A
6/30/2016	710	-139	N/A	-38	N/A
3/31/2016	648	-229	N/A	-82	N/A
12/31/2015	646	-210	N/A	-109	N/A
9/30/2015	636	-95	N/A	-116	N/A
6/30/2015	627	-85	N/A	-188	N/A
3/31/2015	617	-51	N/A	-381	N/A
12/31/2014	570	-57	N/A	-487	N/A
9/30/2014	449	-146	N/A	-593	N/A
6/30/2014	440	-138	N/A	-671	N/A
3/31/2014	391	-204	N/A	-358	N/A
12/31/2013	429	-155	N/A	-263	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ORX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.2%).

Beneficios vs. Mercado: Se prevé que ORX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ORX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (11.3% al año) de ORX crezcan más rápidamente que los del mercado Swedish (0.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 11.3% al año) de ORX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ORX se prevé que sea elevada dentro de 3 años.

Orexo Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 14% to kr18.50

No longer forecast to breakeven

Consensus EPS estimates fall by 45%

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 10% to kr21.50

Consensus EPS estimates upgraded to kr1.95 loss

Recent updates

New minor risk - Share price stability

Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Price target decreased by 14% to kr18.50

No longer forecast to breakeven

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) Initiates New Study of OX640 in Participants with Allergic Rhinitis

Orexo AB (publ) Announces Nomination Committee for the Annual General Meeting 2025

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Consensus EPS estimates fall by 45%

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 10% to kr21.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Consensus EPS estimates upgraded to kr1.95 loss

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%